Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864681 | 1.00 | GRIN1 (0.48) | GRIN1GRIN2AGRIN2BFOLH1HSD17B10 | |
| SCHEMBL16925973 | 1.00 | GRIN1 (0.48) | GRIN1GRIN2AGRIN2BFOLH1HSD17B10 | |
| SCHEMBL210579 | 1.00 | GRIN1 (0.48) | GRIN1GRIN2AGRIN2BFOLH1HSD17B10 | |
| SCHEMBL27143361 | 1.00 | GRIN1 (0.48) | GRIN1GRIN2AGRIN2BFOLH1HSD17B10 | |
| SCHEMBL1079076 | 1.00 | GRIN1 (0.48) | GRIN1GRIN2AGRIN2BFOLH1HSD17B10 | |
| SCHEMBL16925972 | 0.96 | GRIN1 (0.47) | GRIN1GRIN2AGRIN2BFOLH1TP53 | |
| SCHEMBL16922664 | 0.95 | GRIN1 (0.45) | GRIN1GRIN2AGRIN2BFOLH1HSD17B10 | |
| SCHEMBL16922665 | 0.95 | GRIN1 (0.45) | GRIN1GRIN2AGRIN2BFOLH1HSD17B10 | |
| SCHEMBL436048 | 0.95 | GRIN1 (0.45) | GRIN1GRIN2AGRIN2BFOLH1HSD17B10 | |
| SCHEMBL24220975 | 0.94 | GRIN1 (0.44) | GRIN1GRIN2AGRIN2BFOLH1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367305-A1 | ALBUMIN NANOCOMPOSITE COMPRISING PHYTOCHEMICAL AND COMPOSITION FOR IMPROVING MUSCLE DISEASE CONTAINING SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-12-04 | — | — | US | claimed |
| US-20250276071-A1 | NANOPLATFORM FOR TARGETING INFLAMMATORY MACROPHAGES, AND COMPOSITION CONTAINING SAME FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | CLICHEMBIO, INC (KR) | 2025-09-04 | — | — | US | claimed |
| EP-4585209-A1 | NANOPLATFORM FOR TARGETING INFLAMMATORY MACROPHAGES, AND COMPOSITION CONTAINING SAME FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | Clichembio, Inc. (KR) | 2025-07-16 | — | — | EP | claimed |
| WO-2024177490-A1 | ALBUMIN NANOCOMPOSITE COMPRISING PHYTOCHEMICAL AND COMPOSITION FOR IMPROVING MUSCLE DISEASE CONTAINING SAME | 서울대학교산학협력단 | 2024-08-29 | — | — | WO | claimed |
| US-20240199722-A1 | NANOPLATFORM FOR TARGETING MACROPHAGE AND COMPOSITION FOR PREVENTION OR TREATMENT OF METASTATIC CANCER | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2024-06-20 | — | — | US | claimed |
| EP-4380633-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | Rayzebio, Inc. (US) | 2024-06-12 | — | — | EP | claimed |
| WO-2024112181-A1 | NANOPLATFORM FOR TARGETING INFLAMMATORY MACROPHAGES, AND COMPOSITION CONTAINING SAME FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | (주)클리켐바이오 | 2024-05-30 | — | — | WO | claimed |
| US-20240123098-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. | 2024-04-18 | — | — | US | claimed |
| US-11819556-B2 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2023-11-21 | — | — | US | claimed |
| CN-117065056-A | Radionuclide-labeled 1B50-1 antibody and preparation method and application thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2023-11-17 | — | — | CN | claimed |
| US-20220175975-A1 | HER3 Peptides for Imaging and Radiotherapy | THE GENERAL HOSPITAL CORPORATION | 2022-06-09 | — | — | US | claimed |
| US-11241511-B2 | HER3 peptides for imaging and radiotherapy | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| US-20220031873-A1 | Multi-Modal Contrast Agent For Medical Imaging | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2022-02-03 | — | — | US | claimed |
| CN-113444146-A | Targeted fibroblast activation protein probe, preparation method and application thereof in preparation of PET (polyethylene terephthalate) imaging agent | 南方医科大学南方医院 | 2021-09-28 | — | — | CN | claimed |
| CN-112142739-A | Folic acid receptor-targeted radioactive folic acid derivative and preparation method and application thereof | 上海交通大学医学院附属仁济医院 | 2020-12-29 | — | — | CN | claimed |
| US-20200121814-A1 | HER3 Peptides for Imaging and Radiotherapy | UNITED STATES GOVERNMENT | 2020-04-23 | — | — | US | claimed |
| US-20190321495-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-10-24 | — | — | US | claimed |
| US-10130725-B2 | Method for labeling exosomes with radioactive substance and use thereof | SNU R&DB FOUNDATION (KR) | 2018-11-20 | — | — | US | claimed |
| WO-2018126183-A2 | HER3 PEPTIDES FOR IMAGING AND RADIOTHERAPY | THE GENERAL HOSPITAL CORPORATION (US) | 2018-07-05 | — | — | WO | claimed |
| US-20170143856-A1 | METHOD FOR LABELING EXOSOMES WITH RADIOACTIVE SUBSTANCE AND USE THEREOF | SNU R&DB FOUNDATION (KR) | 2017-05-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199722-A1 | NANOPLATFORM FOR TARGETING MACROPHAGE AND COMPOSITION FOR PREVENTION OR TREATMENT OF METASTATIC CANCER | SIGLEC9, B3GNT2, NEU3 | GRIN1 3195/4885GRIN2A 3330/4885GRIN2B 3594/4885 |
| US-20250276071-A1 | NANOPLATFORM FOR TARGETING INFLAMMATORY MACROPHAGES, AND COMPOSITION CONTAINING SAME FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | GLS, TNF, ARG2 | GRIN1 864/4885GRIN2A 1216/4885GRIN2B 1915/4885 |
| US-11819556-B2 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | GRIN1 3937/4885GRIN2A 4103/4885GRIN2B 4456/4885 |
| US-20220175975-A1 | HER3 Peptides for Imaging and Radiotherapy | ERBB3, EGFR, NGLY1 | GRIN1 2533/4885GRIN2A 3766/4885GRIN2B 2840/4885 |
| US-20250367305-A1 | ALBUMIN NANOCOMPOSITE COMPRISING PHYTOCHEMICAL AND COMPOSITION FOR IMPROVING MUSCLE DISEASE CONTAINING SAME | ALB, TNNC1, MYOF | GRIN1 4527/4885GRIN2A 4636/4885GRIN2B 4705/4885 |
| US-11241511-B2 | HER3 peptides for imaging and radiotherapy | ERBB3, EGFR, NGLY1 | GRIN1 2533/4885GRIN2A 3766/4885GRIN2B 2840/4885 |
| US-20200121814-A1 | HER3 Peptides for Imaging and Radiotherapy | ERBB3, EGFR, NGLY1 | GRIN1 2533/4885GRIN2A 3766/4885GRIN2B 2840/4885 |
| US-20190321495-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, MKI67 | GRIN1 3696/4885GRIN2A 4714/4885GRIN2B 4645/4885 |
| US-20240123098-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | TFRC, SLC39A14, EGFR | GRIN1 3937/4885GRIN2A 4103/4885GRIN2B 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.